// App-Quantinova.ai

: Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001).

Researchers

Presenter

  • Thomas Powles

Principal Investigators

  • Evan Y. Yu

  • Gopa Iyer

  • Matthew T Campbell

  • Yohann Loriot

  • Maria De Santis

  • Peter H. O'Donnell

  • Earle F Burgess

  • Andrea Necchi

  • Laurence E. M. Krieger

  • Nobuaki Matsubara

  • Vadim S Koshkin

  • Wei Zhang

  • Mari Ichimaru

  • Matt D. Galsky

Medical Centers

  • Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Atrium Health, Levine Cancer Institute, Charlotte, NC

  • University of Chicago Comprehensive Cancer Center, Chicago, IL

  • Institut de Cancérologie Gustave Roussy, Université Paris-Saclay, Villejuif, France

  • University of Washington School of Medicine, Seattle, WA

  • Genesis Care, North Shore, Sydney, NSW, Australia

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Vita-Salute San Raffaele University,

  • Charite Univsmedizin Berlin, Berlin, Germany

  • National Cancer Center Hospital, Tokyo, Japan

  • Barts Health NHS Trust, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • 1.MD Anderson Cancer Center, Houston, TX

Locations

  • Germany

  • Italy

  • France

  • Japan

  • Australia

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT04879329

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved